robustness of phospho akt-mtor pathway assay...

Penny Jensen1; Bhavin Patel1; Leigh Foster1; Aaron Gajadhar2; Sebastien Gallien3; Jonathan R. Krieger4; Jiefei Tong5; Michael F. Moran4,5,6; Rosa Viner2; Andreas Huhmer2; Kay Opperman1; John Rogers1

1Thermo Fisher Scientific, Rockford, IL; 2Thermo Fisher Scientific, San Jose, CA; 3Thermo Fisher Scientific, PMSC, Cambridge, MA; 4SPARC Biocentre, The Hospital for Sick Children, Toronto, Canada; 5Program in Cell Biology, The Hospital for Sick

Children, Toronto, Canada; 6Department of Molecular Genetics, University of Toronto, Canada

RESULTS

ABSTRACT Purpose: The AKT/mTOR pathway plays a central role in tumor progression and drug resistance. Quantitative

measurement of alterations in the expression of pathway proteins and post-translational modifications (PTM) is necessary

for understanding cancer biology. Highly accurate monitoring of these pathway proteins has not been achieved, due to

poor reproducibility, unreliable quantitation, and lack of standardized methods and reagents. To overcome these

challenges, the novel SureQuantTM pathway panels have been applied, which utilize an optimized multiplex

immunoprecipitation to targeted mass spectrometry (mIP-tMS) workflow. SureQuant assays can quantitate multiple

proteins, PTMs and interacting partners, which creates new possibilities for a broad range of applications, including

cancer, drug development, and research into precision medicine.

Methods: The SureQuant total and phospho pathway panels contain two modules: 1) The IP-MS Sample Prep Module

includes reagents necessary to immunoenrich AKT pathway, RAS, or TP53 proteins, and perform MS sample preparation

in one day 2) The Absolute or Relative Quantitation Modules include a Pierce™ LC-MS/MS System Suitability Standard,

AQUA Ultimate Heavy and/or AQUA Ultimate Light Peptides, and verified MS instrument and data analysis methods.

Serum-starved, inhibitor-treated (LY294002/NVP-BEZ235/Rapamycin) HCT116, A549, and MCF7 cells were stimulated

with hIGF-1. SureQuant AKT pathway panels (total and phospho) were used to determine the absolute concentration of

target peptides using targeted MS analysis. The panels were benchmarked against Western blotting using three

unstimulated, hIGF-1 stimulated or inhibited cell lysates, as well as several tissue/xenograft lysates.

Results: Previously, we verified antibodies and target peptides to AKT and RAS pathways using an optimized mIP-tMS

workflow. From the standard curve, all target peptides were monitored with <20% CV, 3 orders of magnitude dynamic

range, linearity (R2) >0.97, and accuracy of 80-120% in a complex matrix. Using the SureQuantTM pathway panels,

absolute quantitation of 37 target peptides in unknown samples was achieved with <20% CV across multiple cancer cell

lines. The SureQuant pathway analysis workflow allowed absolute quantitation of target peptides from positive control

lysate with <15% individual operator %CV and <20% combined %CV using PRM analysis. Kit performance was evaluated

through analysis of abundance levels between three different cancer cell lines, A549, HCT116, and MCF7, using the

SureQuant AKT Total and Phospho assay showed preferences for certain inhibitors in specific cell lines treated with hIGF-

1. The PI3K inhibitor LY294002 functioned the best in HCT116 cells whereas the dual PI3K/Rapamycin inhibitor NVP-

BEZ235 worked predominantly in A549 cells. Analysis by mass spectrometry allowed for more accurate and informative

data with the determination of fmol levels of protein expression and capability to discriminate between isoforms of many

proteins that are unable to procure with western blot analysis. Absolute quantitation of 12 phosphorylated AKT pathway

targets was obtained from five patient derived lung tumor xenograft samples. Additionally, all 12 total and 12 phospho

AKT pathway targets were quantitated from three different tissue lysates, Lung, Large Intestine, and Breast tumor.

CONCLUSIONS

▪ PierceTM LC-MS/MS System Suitability Standard (7 x 5 mixture) achieves appropriate linearity and dynamic range to assess

system performance prior to acquisition of unknown samples.

▪ SureQuantTM Multiplex IP-MS and Absolute Quantitation Modules for AKT pathway proteins allowed simultaneous absolute

quantitation of multiple total and phospho AKT pathway proteins in treated cell lines and tumor samples with high accuracy

and precision (CV <20%).

▪ Analysis of abundance levels between three different cancer cell lines using the SureQuantTM AKT Total and Phospho kits

revealed preferences for certain inhibitors in specific cell lines, with PI3K inhibitor LY294002 demonstrating highest efficacy

in HCT116 cells, whereas the dual PI3K/Rapamycin inhibitor NVP-BEZ235 was most effective in A549 cells. Orthogonal

evaluation between PRM assays and Western Blot analysis of three cancer cell lines treated with hIGF-1 and various

inhibitors, showed similar trends in the protein expression changes, albeit the level of precision and dynamic range

achieved with the SureQuant kit is difficult or impossible to achieve with Western Blot analysis.

▪ SureQuantTM AKT pathway kits are amenable to diverse sample sources and allowed identification of target proteins from

cell lysate, tissues and patient derived xenograft tissue samples.

▪ SureQuantTM AKT pathway kits are amenable to diverse sample sources and allowed identification of target proteins from

cell lysate, tissues and patient derived xenograft tissue samples.

REFERENCES1. Logue JS, Morrison DK. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev. 2012 Apr 1; 26(7):641-50.

2. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011 Jun;36(6):320-8

3. Carr SA, Abbatiello SE, Ackermann BL et al. Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay

Development Using a Fit-for-Purpose Approach. Mol Cell Proteomics. 2014 Mar; 13(3):907-17.

4. Ackermann BL . Understanding the role of immunoaffinity-based mass spectrometry methods for clinical applications. Clin Chem. 2012 Dec; 58(12):1620

TRADEMARKS ANDS LEGAL INFORMATION

© 2019 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries.

This information is not intended to encourage use of these products in any manner that might infringe the intellectual property rights of

others.

Applications of Mass Spectrometry Targeted Assays for Quantitative Analysis of Cancer Signaling Proteins

MATERIALS AND METHODS

Figure 1. Thermo Scientific™ SureQuant™ Multiplex IP to Targeted MS Modules & Kits

• 10 reactions (samples)

• Biotinylated antibodies mix

• Positive control lysate

• Streptavidin magnetic beads

• Wash buffers (A and B)

• Trypsin

• Sample prep buffer

• Reduction/alkylation reagents

• 10% TFA

• Low-binding tubes


• AQUA heavy peptide mix

• AQUA light peptide mix

• 6 protein digest matrix

• 7 x 5 system suitability standard

• Peptide Diluent

• Instrument method with Skyline doc


Relative quantitation module


• AQUA heavy peptide mix

• 7 x 5 system suitability standard

• Peptide Diluent

• Instrument method with Skyline doc


AKT pathway:

total targets

AKT pathway:

phospho targets

AKT1/AKT2/

AKT3

PTEN

IRS1

IGF1R

GSK3a

GSK3b

PRAS40

(AKT1S1)

mTOR

P70S6K

TSC2

AKT1/AKT2

pSer473/pSer474

PTEN pSer380

IRS1 pSer312

IGF1R

pTyr1162/1163

GSK3a pSer21

GSK3b pSer9

PRAS40 pThr246

mTOR pSer2448

P70S6K pThr389

TSC2 pSer939

IP/MS sample prep module Absolute quantitation module

Cell Lines and Tissue Lysate: A549, HCT116 and MCF7 cells were grown in Ham’s F-12K media, McCoy’s 5A Media

and DMEM Media, respectively, with 10% FBS/1xPenStrep to ~70-80% confluency. Cells were serum starved with 0.1%

charcoal stripped FBS for 24 hours before stimulation with 100 ng/mL of IGF for 15 minutes. Breast, Lung, and Large

Intestine Tumor and Normal Adjacent Tissue were purchased from BioIVT. Cells and tissue samples were lysed with IP

Lysis buffer (Thermo Fisher Scientific PN#87788) supplemented with 1X HALT Protease and Phosphatase inhibitor

cocktail (Thermo Fisher Scientific PN#78440).

Multiplex Immunoprecipitation to MS Sample Preparation and MS Quantitation: The SureQuantTM IP and MS

Sample Preparation Modules for AKT Pathway (PN# A40081, A40086, A40091), were used to immunoenrich relevant

protein targets. The SureQuantTM Absolute Quantitation Modules for AKT Pathway (PN# A40083, A40093) was used to

generate calibration curves and determine concentrations of target peptides from unknown samples.

Liquid Chromatography and Mass Spectrometry: PierceTM LC-MS/MS System Suitability Standard (7 x 5 Mixture)

(PN# A40010) was used to assess dynamic range and sensitivity (LLOQ) of the nanoLC-MS system prior to running

calibration curves or unknown samples. IP-enriched and trypsin digested samples were then desalted on-line using the

Thermo Scientific™ Acclaim™ PepMap 100 C18 Trap Column (PN#164564) followed by seperation using a Thermo

Scientific™ EASY-Spray C18 column (PN#ES800). For discovery MS and targeted PRM-MS analysis, the samples were

analyzed using the Thermo Scientific™ Dionex™ UltiMate™ 3000 RSLCnano System and Thermo Scientific™ Q

Exactive™ HF Hybrid Quadrupole-Orbitrap Mass Spectrometer. Verified instrument acquisition methods were used, as

well as inclusion lists relevant to each Absolute Quantitation Module.

MS Data Analysis: Discovery MS data were analyzed with Thermo Scientific™ Proteome Discoverer™ to assess percent

sequence coverage, unique peptides, areas/intensities of identified peptides, and PTMs. For targeted MS data analysis,

Skyline software (University of Washington) were used to measure limit of quantitation (LOQ) from the calibration curve

and target analyte concentration from unknown samples.

hIGF-1 Stimulation

Figure 2. Experimental Workflow for Multiplex IP-MS Assays Figure 3. AKT Pathway

Protein Elution

1 h

Traditional MS Sample Prep Workflow for IP

SureQuantTM Target Assay MS Sample Prep Workflow for IP

Protein

Elution

0.2h 1h 0.5h 0.5h 18.5h

1 h

Dry Samples Alkylation

Reduction Protein DigestionDry and reconstitute

~21 hours

total

~4 hours total 1h 0.1h

Protein DigestionReduction

Alkylation Dry and reconstitute

2h

Figure 4. MS Sample Prep Workflow Optimization for Immuno-enriched (IP) Samples

INTRODUCTIONMultiplex Immunoprecipitation to Mass spectrometry (IP-MS) kits from Thermo Fisher Scientific are developed for simultaneous

enrichment and quantitation of total abundance and phosphorylation levels of multiple proteins from the AKT/mTOR Signaling

Pathway. The immunoenriched, digested samples are spiked with heavy peptide internal standards, which can then be

processed using discovery MS (DDA) and targeted MS (PRM) methods for analysis.

y = 0.935x + 7.4654R² = 0.9971

6

7

8

9

10

11

12

-1 0 1 2 3

1: GISNEGQNASIK

y = 0.9327x + 7.5556R² = 0.9969

6

7

8

9

10

11

12

-1 0 1 2 3

2: IGDYAGIK

y = 0.9832x + 7.4441R² = 0.9963

6

7

8

9

10

11

12

-1 0 1 2 3

3: TASEFDSAIAQDK

y = 1.0553x + 7.1621R² = 0.9971

6

7

8

9

10

11

12

-1 0 1 2 3

4: ELGQSGVDTYLQTK

y = 0.8584x + 7.026R² = 0.9851

6

7

8

9

10

11

12

-1 0 1 2 3

5: SFANQPLEVVYSK

y = 1.0769x + 7.1064R² = 0.993

6

7

8

9

10

11

12

-1 0 1 2 3

6: LTILEELR

y = 1.2028x + 5.6947R² = 0.9923

4

5

6

7

8

9

10

-1 0 1 2 3

7: ELASGLSFPVGFK

RT: 10.00 - 35.00 SM: 7B

10 12 14 16 18 20 22 24 26 28 30 32 34

Time (min)

0

10

20

30

40

50

60

70

80

90

100

Rela

tive A

bundance

17.27

620.8320.30

433.2625.00

783.41

31.65

691.4029.17

509.33

22.39

703.35

27.29

754.91

20.68

433.2620.03

461.7722.81

703.8425.43

783.9133.79

845.5316.98

556.80

30.63

561.8110.07

371.3112.40

371.10

13.47

371.10

NL:

1.94E8

Base Peak

F: ms MS

DDA_7x5mi

x_200fmolO

C_R1

7x5 Mixture: Peptide Groups Calibration CurvesPeptide

GroupPeptide Sequence

Precursor m/z

(Isotope label)

Conc on

Column (fmol)

1

GISNEGQNA[+4]S[+4]I[+7]K[+8] 620.8324++ (4 heavy) 200

GISNEGQNA[+4]SI[+7]K[+8] 618.8289++ (3 heavy) 20

GISNEGQNASI[+7]K[+8] 616.8253++ (2 heavy) 2

GISNEGQNASIK[+8] 613.3168++ (1 heavy) 0.5

GISNEGQNASIK 609.3097++ 0.0125

Figure 5. PierceTM LC-MS/MS System Suitability Standard (7 x 5 Mixture)

LLOQ/Linearity

Calibration curve generated for each peptide set of 5 isotopologues of the same peptide sequence showed >3 orders of

magnitude dynamic range and linearity (R2) ≥ 0.9800

Figure 6. Determination of Quantitation Limits and Linearity of AQUA Light Peptides for

SureQuantTM Pathway Kits

Calibration

Curve PointsFmol on column

CC1 200.00

CC2 20.00

CC3 2.00

CC4 0.50

CC5 0.13

CC6 0.03

0.95

0.96

0.97

0.98

0.99

1

1.01

Lin

ea

rity

(R

2)

AKT Pathway Target Peptides Linearity (R2)

y = 1.0076x - 1.2741

R² = 0.9993-3

-2

-1

0

1

2

-2 -1 0 1 2 3

AKT1: NDGTFIGYK

0

0.2

0.4

0.6

LL

OQ

(fm

ol)

AKT Pathway Target Peptides Limit of quantitation (LLOQ)

All 30 AKT pathway target peptides

were monitored with linear quantitation

(R2 ≥ 0.9800) and 2-3 orders of

magnitude (LLOQ ≤ 0.5 fmol on column)

Figure 7. Precision of AKT/mTOR Signaling Pathway Proteins Using SureQuantTM Targeted MS Kits

-10%

10%

30%

%C

V

-10%

10%

30%

%C

V

AKT SureQuantTM Pathway Mass Spec Assay kits allowed absolute quantitation of target peptides from positive control

lysate with <15% individual CV and <20% combined CV using PRM analysis.

0%

5%

10%

15%

20%

25%

30% Op1_CV

Op2_CV

Op3_CV

Combined CV

PRM quant specs:

• Individual CV <15%

• Combined CV <20%

All peptides for 11

targets passed CV

specs

Robustness of Phospho AKT-mTOR Pathway Assay Kit

%C

V

Figure 9. Absolute or Relative Quantitation of AKT/mTOR Signaling Pathway Proteins Using

SureQuantTM kits

AKT/mTOR pathway proteins were enriched through multiplex immunoprecipitation using the SureQuant™ AKT Pathway or AKT

Phospho Pathway Mass Spec Assay kit. Analyses were performed on a Thermo Scientific™ Q Exactive™ HF Orbitrap™ mass

spectrometer using directed discovery (DDA) and targeted MS (PRM) acquisition methods. DDA and PRM data were analyzed

in Proteome Discoverer and Skyline software, respectively. PRM analysis using the calibration curve allowed absolute

quantitation of each target peptide from positive control lysate. Western Blot data showed differential expression for

phosphorylated AKT pathway proteins with hIGF-1 stimulation and inhibitor treatments

Mar

ker

Unt

reat

edhI

GF-

1LY

2940

02/h

IGF-

1Ra

pam

ycin

/hIG

F-1

LY2+

Rap/

hIG

F-1

BEZ2

35/h

IGF-

1

MCF7 lysate HCT116 lysate

pAKT

Mar

ker

Unt

reat

edhI

GF-

1LY

2940

02/h

IGF-

1Ra

pam

ycin

/hIG

F-1

LY2+

Rap/

hIG

F-1

BEZ2

35/h

IGF-

1

72 -55 -

95 -

A549 lysate

72 -55 -

95 -

72 -55 -

95 -

Mar

ker

Unt

reat

edhI

GF-

1LY

2940

02/h

IGF-

1Ra

pam

ycin

/hIG

F-1

LY2+

Rap/

hIG

F-1

BEZ2

35/h

IGF-

1

72 -95 -130 -

pIGF1R 72 -95 -130 -

72 -95 -130 -

pPTEN 72 -55 -

72 -55 -

72 -55 -

pGSK3A

pGSK3B

pPRAS40

pmTOR

pRPS6KB1

72 -55 -

72 -55 -

72 -55 -

55 -

36-

55 -

36-

55 -

36-

cyclophilinB

55 -

36-

55 -

36-

55 -

36-

250 - 250 - 250 -

72 -55 -

72 -55 -

72 -55 -

28 -

17 -

28 -

17 -

28 -

17 -

0.00

10.00

20.00

30.00

13901 11931 11391 11373 11133 Positive

Ab

solu

te C

on

c/IP

(fm

ol) pAKT1

Peptide #2

Peptide #1

0.00

1.00

2.00

3.00

13901 11931 11391 11373 11133 Positive

Ab

solu

te C

on

c/IP

(fm

ol) pAKT2Peptide #2

Peptide #1

0.00

1.00

2.00

3.00

4.00

13901 11931 11391 11373 11133 Positive

Ab

solu

te C

on

c/IP

(fm

ol)

pAKT3Peptide #2Peptide #1

0.00

50.00

100.00

150.00

200.00

13901 11931 11391 11373 11133 Positive

Ab

solu

te C

on

c/ P

I (f

mo

l)

pAKT1S1Peptide #2

Peptide #1

0.00

10.00

20.00

30.00

40.00

50.00

13901 11931 11391 11373 11133 Positive

Ab

solu

te C

on

c/IP

(fm

ol) pGSK3A

Peptide #2Peptide #1

0.00

10.00

20.00

30.00

40.00

13901 11931 11391 11373 11133 Positive

Ab

solu

te C

on

c/IP

(fm

ol)

pGSK3BPeptide #1Peptide #2Peptide #3

0.00

10.00

20.00

30.00

40.00

13901 11931 11391 11373 11133 Positive

Ab

solu

te C

on

ce/I

P (

fmo

l)

pIGF1RPeptide #3Peptide #2Peptide #1

0.00

1.00

2.00

3.00

13901 11931 11391 11373 11133 Positive

Ab

solu

te C

on

c/IP

(fm

ol)

pIRS1Peptide #2

Peptide #1

0.00

20.00

40.00

60.00

13901 11931 11391 11373 11133 Positive

Ab

solu

te C

on

c/IP

(fm

ol) pMTOR

Peptide #1

Peptide #4

Peptide #3

0.00

5.00

10.00

15.00

20.00

13901 11931 11391 11373 11133 Positive

Ab

solu

te C

on

c/IP

(fm

ol)

pPTENPeptide #3Peptide #2Peptide #1

0.00

20.00

40.00

60.00

13901 11931 11391 11373 11133 Positive

Ab

solu

te C

on

c/IP

(fm

ol)

pRPS6KB1Peptide #2Peptide #1

0.00

5.00

10.00

15.00

20.00

25.00

13901 11931 11391 11373 11133 Positive

Ab

solu

te C

on

c/IP

(fm

ol)

pTSC2Peptide #3Peptide #2Peptide #1

Figure 12. Phospho AKT Pathway Proteins PRM Data from Lung Cancer Patient Xenograft Samples.

Accurate quantitation was obtained from five patient derived lung tumor xenograft samples using the SureQuantTM AKT Phospho

Pathway kit. Patient derived xenograft samples were lysed in 2% SDS before multiplex IP enrichment followed by Targeted MS (PRM)

analysis using the Thermo Scientific™ Q Exactive™ HF-X and EASY-nLC 1200 system. A 50cm EASY-Spray column (ES803) in

direct-injection setup was used for all LC-MS data acquisition and Skyline Software was used to generate standard curves (data not

shown) and calculate absolute concentrations of unknown samples.

Calculated concentration (fmol) values were used to summarize data where an increase in phosphorylation was designated

by at least a 40% increase compared to untreated. Inhibition was designated if below 40% hIGF-1 treated value. All pathway

phosphorylated proteins showed increase in abundance with hIGF-1 treatment across all three cell lines, whereas inhibitors

functioned differently among three cell lines:

• The PI3K inhibitor (LY294002) was more effective than the mTOR inhibitor (Rapamycin) with effectiveness HCT116

> MCF7 > A549

• Combined LY294002 + Rapamycin treatment was most effective in HCT116 cells with effectiveness HCT116 > A549

> MCF7

• Dual inhibitor (NVP-BEZ235) worked best in A549 cells compared to LY294002 and Rapamycin together with

effectiveness A549 > HCT116 > MCF7

Figure 10. Summary of Quantitative Changes in Phospho AKT Pathway following Targeted

Inhibition

hIGF-1 Stimulation

LY294002

PI3K inhibitorRapamycin

mTOR inhibitor

NVP-BEZ235

mTOR and

PI3K inhibitor

13.3

2.20.6

13.5

17.5

31.6

1.4 0.6

4.87.8

0.3 1.4

18.9

5.0

0.5

29.5

33.4

54.4

0.1 1.13.5

9.5

0.62.0

0

10

20

30

40

50

60

fmo

l tar

get

Lung NormalLung Tumor

1.0

0.5

1.7

1.3

3.0

1.0

0.0 0.2

5.7

1.4

0.20.40.3 0.3 0.3 0.2

3.7

1.4

0.00.3

2.1

5.6

0.2 0.2

0

1

2

3

4

5

6

7

fmo

l tar

get

Lung NormalLung Tumor

Figure 8. Quantitation of Total and Phospho AKT Pathway Proteins using Different Positive

Control Lysate Amounts

Total PhosphoLung Tissue

Breast

Large Intestine

8.5

2.1 0.4

6.1 5.9 4.70.8 1.3

3.5 1.6 0.1 0.8

37.1

18.4

0.4

55.1

84.0

72.3

0.6 2.6

18.3

11.6

0.45.1

0

10

20

30

40

50

60

70

80

90

fmo

l tar

get

Breast Normal

Breast Tumor

0.4 0.40.9 0.6 0.4 0.3 0.0 0.1

2.2

0.40.1 0.3

0.7 0.6 0.6 0.31.1 1.1

0.00.4

10.6

4.9

0.2 0.5

0

2

4

6

8

10

12

fmo

l tar

get

Breast NormalBreast Tumor

7.3

1.0 0.3

16.5

20.8 20.2

1.2 0.2

7.9

0.9 0.2 0.7

16.2

2.80.8

19.9

32.2

43.3

0.7 0.6

5.3

0.7 0.2 1.3

0

10

20

30

40

50

60

fmo

l tar

get

Lg Intestine Normal

Lg Intestine Tumor

0.5 0.20.8 0.6

2.0

0.70.0 0.1

12.0

0.2 0.1 0.30.6 0.4 0.70.2

1.9

1.0

0.0 0.2

4.0

0.4 0.2 0.3

0

2

4

6

8

10

12

14

16

fmo

l tar

get

Lg Intestine Normal

Lg Intestine Tumor

SureQuantTM AKT Total and Phospho Pathway kits allowed accurate quantitation from lung, breast, and large intestine

normal and tumor tissue lysates. Skyline Software was used to generate standard curves and calculate absolute

concentrations of unknown samples.

Figure 11. Quantitation of Total and Phospho AKT Pathway Proteins in Lung, Breast, and Large

Intestine Normal and Tumor Tissue Samples.

0

20

40

60

80

100

120

50 µg 100 µg 200 µg 500 µg 1000 µg

fmo

l tar

get

lysate amount

Phospho AKT hIGF-1 MCF7 lysate pAKT1pAKT2pAKT3pAKT1S1pGSK3ApGSK3BpIGF1RpIRS1pmTORpPTENpKS6KB1

0

50

100

150

200

250

50 µg 100 µg 200 µg 500 µg 1000 µg

fmo

l tar

get

lysate amount

Total AKT hIGF-1 A549 lysateAKT1AKT2AKT3AKT1S1GSK3AGSK3BIGF1RIRS1mTORPTENKS6KB1

Total and phospho AKT pathway PRM analysis allowed absolute quantitation of all target peptides from 50 µg to 1000 µg of

positive control lysate. Overall linear correlation between lysate amount and target quantitation was observed.

robustness of phospho akt-mtor pathway assay...

Documents